Cargando…

Targeting chronic lymphocytic leukemia using CIGB-300, a clinical-stage CK2-specifc cell-permeable peptide inhibitor

Chronic lymphocytic leukemia (CLL) remains an incurable malignancy, urging for the identifcation of new molecular targets for therapeutic intervention. CLL cells rely on overexpression and hyperactivation of the ubiquitous serine/threonine protein kinase CK2 for their viability in vitro. CIGB-300 is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martins, Leila R., Perera, Yasser, Lúcio, Paulo, Silva, Maria G., Perea, Silvio E., Barata, João T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2013
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960206/ https://www.ncbi.nlm.nih.gov/pubmed/24473900

Ejemplares similares

Preclinical efficacy of CIGB-300, an anti-CK2 peptide, on breast cancer metastasic colonization
por: Gottardo, Maria F., et al.
Publicado: (2020)

Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300
por: Rosales, Mauro, et al.
Publicado: (2021)

CIGB-300-Regulated Proteome Reveals Common and Tailored Response Patterns of AML Cells to CK2 Inhibition
por: Rosales, Mauro, et al.
Publicado: (2022)

CIGB-300 Peptide Targets the CK2 Phospho-Acceptor Domain on Human Papillomavirus E7 and Disrupts the Retinoblastoma (RB) Complex in Cervical Cancer Cells
por: Ramón, Ailyn C., et al.
Publicado: (2022)

CIGB-300 Anticancer Peptide Differentially Interacts with CK2 Subunits and Regulates Specific Signaling Mediators in a Highly Sensitive Large Cell Lung Carcinoma Cell Model
por: Pérez, George V., et al.
Publicado: (2022)

Gene expression profiling unveils the temporal dynamics of CIGB-300-regulated transcriptome in AML cell lines
por: Vázquez-Blomquist, Dania, et al.
Publicado: (2023)

The synthetic peptide CIGB-300 modulates CK2-dependent signaling pathways affecting the survival and chemoresistance of non-small cell lung cancer cell lines
por: Cirigliano, Stéfano M., et al.
Publicado: (2017)

Optimizing CIGB-300 intralesional delivery in locally advanced cervical cancer
por: Sarduy, M R, et al.
Publicado: (2015)

Clinical-Grade Peptide-Based Inhibition of CK2 Blocks Viability and Proliferation of T-ALL Cells and Counteracts IL-7 Stimulation and Stromal Support
por: Perera, Yasser, et al.
Publicado: (2020)

Specifcations d'un dispositif de mesures optiques
por: Lohmann, KD
Publicado: (1969)

Predicting CK2 beta-dependent substrates using linear patterns
por: Núñez de Villavicencio-Díaz, Teresa, et al.
Publicado: (2015)

Proteomic Study to Survey the CIGB-552 Antitumor Effect
por: Rodríguez-Ulloa, Arielis, et al.
Publicado: (2015)

Multifaceted CK2 in malignant and healthy T cells
por: Ribeiro, Sérgio T., et al.
Publicado: (2017)

Therapeutic targeting of CK2 in acute and chronic leukemias
por: Buontempo, F, et al.
Publicado: (2018)

The Antitumor Peptide CIGB-552 Increases COMMD1 and Inhibits Growth of Human Lung Cancer Cells
por: Fernández Massó, Julio R., et al.
Publicado: (2013)

The Anticancer Peptide CIGB-552 Exerts Anti-Inflammatory and Anti-Angiogenic Effects through COMMD1
por: Daghero, Hellen, et al.
Publicado: (2020)

Data for comparative proteomics analysis of the antitumor effect of CIGB-552 peptide in HT-29 colon adenocarcinoma cells
por: Núñez de Villavicencio-Díaz, Teresa, et al.
Publicado: (2015)

Phosphoproteomic Landscape of AML Cells Treated with the ATP-Competitive CK2 Inhibitor CX-4945
por: Rosales, Mauro, et al.
Publicado: (2021)

Targeting of Protein Kinase CK2 Elicits Antiviral Activity on Bovine Coronavirus Infection
por: Ramón, Ailyn C., et al.
Publicado: (2022)

Repurposing drugs to target nonalcoholic steatohepatitis: Auranofin, a gold-organic molecule complex for the treatment of a specifc complex trait
por: Pirola, Carlos J., et al.
Publicado: (2022)

Correction: Biosynthesis of a VLP-type nanocarrier specifc to cancer cells using the BEVS expression system for targeted drug delivery
por: Hashemzadeh, Mohammad Sadegh, et al.
Publicado: (2023)

Correction: Telomere and subtelomere high polymorphism might contribute to the specifcity of homologous recognition and pairing during meiosis in barley in the context of breeding
por: Serrano-León, I. M., et al.
Publicado: (2023)

Cell Penetrating Capacity and Internalization Mechanisms Used by the Synthetic Peptide CIGB-552 and Its Relationship with Tumor Cell Line Sensitivity
por: Astrada, Soledad, et al.
Publicado: (2018)

CIGB-258, a peptide derived from human heat-shock protein 60, decreases hyperinflammation in COVID-19 patients
por: Hernandez-Cedeño, M., et al.
Publicado: (2021)

Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial
por: Cruz, Leticia R., et al.
Publicado: (2020)

Syndromic Craniosynostosis Can Define New Candidate Genes for Suture Development or Result from the Non-specifc Effects of Pleiotropic Genes: Rasopathies and Chromatinopathies as Examples
por: Zollino, Marcella, et al.
Publicado: (2017)

HEPATITIS B NUCLEOCAPSID PARTICLE AS IMMUNOPOTENTIATOR OF INNATE AND ADAPTIVE IMMUNITY FOR NASAL VACCINES CIGB 2020 AND MAMBISA AGAINST COVID-19
por: Guillen, G., et al.
Publicado: (2023)

Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial
por: Solares, Ana M., et al.
Publicado: (2011)

Macro-CK and CK-BB Contributing to Sham CK-MB Elevation
por: Wada, Yuki, et al.
Publicado: (2017)

Targeting CK2 mediated signaling to impair/tackle SARS-CoV-2 infection: a computational biology approach
por: Miranda, Jamilet, et al.
Publicado: (2021)

Anti-Inflammatory Activity of CIGB-258 against Acute Toxicity of Carboxymethyllysine in Paralyzed Zebrafish via Enhancement of High-Density Lipoproteins Stability and Functionality
por: Cho, Kyung-Hyun, et al.
Publicado: (2022)

In silico investigations identified Butyl Xanalterate to competently target CK2α (CSNK2A1) for therapy of chronic lymphocytic leukemia
por: Alsagaby, Suliman A., et al.
Publicado: (2022)

CIGB-258 Exerts Potent Anti-Inflammatory Activity against Carboxymethyllysine-Induced Acute Inflammation in Hyperlipidemic Zebrafish via the Protection of Apolipoprotein A-I
por: Cho, Kyung-Hyun, et al.
Publicado: (2023)

Utility of CK8, CK10, CK13, and CK17 in Differential Diagnostics of Benign Lesions, Laryngeal Dysplasia, and Laryngeal Squamous Cell Carcinoma
por: Boricic, Novica, et al.
Publicado: (2022)

Anti-cancer effects of ginsenoside CK on acute myeloid leukemia in vitro and in vivo
por: Hou, Yuzhu, et al.
Publicado: (2022)

An Immunohistochemical Expression of CK5/6, CK7, and CK20 on Cell Blocks in Metastatic Cervical Lymphadenopathy
por: Kaur, Amanpreet, et al.
Publicado: (2022)

Invasive Lobular Carcinomas Do Not Express Basal Cytokeratin Markers CK5/6, CK14 and CK17
por: Khilko, Natalya, et al.
Publicado: (2010)

The Multiple Personalities of the Regulatory Subunit of Protein Kinase CK2: CK2 Dependent and CK2 Independent Roles Reveal a Secret Identity for CK2β
por: Bibby, Ashley C., et al.
Publicado: (2005)

The multifaceted role of protein kinase CK2 in high-risk acute lymphoblastic leukemia
por: Zhou, Yun, et al.
Publicado: (2020)

CK2 and PI(3)K are direct molecular targets of quercetin in chronic lymphocytic leukaemia
por: Russo, Maria, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4d86muc5ua8f452b0ebe0pfa57